California Jury Returns $47+ Million Verdict in Artificial Stone Silicosis Case

Illustration representing PRX3 inhibitor research and its potential role in treating mesothelioma through oxidative stress pathways.

Turning Cancer’s Strength into Its Weakness

August 10, 2026
Diagram showing blood drawn from a human, with a test tube highlighting components: ctDNA, extracellular vesicles, histones and their complexes—including histone H4 hyperacetylation—and circulating tumor cells (CTCs), originating from blood vessels. The illustration emphasizes elements relevant to pleural mesothelioma and the identification of potential prognostic markers.

Histone H4 Hyperacetylation: A Promising New Prognostic Marker in Pleural Mesothelioma

July 31, 2026